National Harm Reduction Technical Assistance and Syringe Services Program (SSP) Monitoring and Evaluation Funding Opportunity

 

The purpose of this program is to strengthen harm reduction programs in order to prevent infectious disease resulting from injection drug use, and improving health outcomes for people who inject drugs; including strengthening linkage to medication-assisted treatment. It is comprised of three components: technical assistance, communications and monitoring and evaluation.

Active 93.488 Centers For Disease Control and Prevention, Department of Health and Human Services B - Project Grants Not applicable. Section 301(a) and 317 (k)(2) of the Public Health Service Act (42 U.S.C. section 241 and 274b), as amended.
Section 318 of the Public Health Service Act (42 U.S.C. Section 247c, as amended) Not applicable. Not applicable. Not applicable. Preapplication coordination is not applicable. This program is excluded from coverage under 2 CFR 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards. After review and approval, a Notice of Award (NoA) will be prepared and processed, along with appropriate notification to the public. Initial awards provide funds for the first budget period (usually 12 months) and the NoA will indicate support recommended for the remainder of the project period, allocation of Federal funds by budget categories, award requirements, and special conditions, if any. Contact the headquarters or regional location, as appropriate for application deadlines From 120 to 180 days. Not applicable. More than 180 days. Cooperative agreement period of performance is 1 to 5 years. After initial awards, and subject to availability of funds, projects may be continued non-competitively contingent upon satisfactory progress by the recipient (as documented in required reports) and the determination that continued funding is in the best interest of the Federal government. Applications will be evaluated on the review criteria described in the Notice of Funding Opportunity Announcements (NOFOs). In general, the review and selection process of complete and responsive applications to the NOFO consists of determination of the scientific and technical merit by objective or peer review, availability of funds, and relevance of program priorities and the priorities of CDC. The purpose of this program is to increase the capacity of government and non-government organizations to strengthen harm reduction programs, including Syringe Services Programs (SSPs). Activities by the cooperative agreement program include technical assistance, communication, and monitoring and evaluation of harm reduction programs. These activities will facilitate and sustain efforts to effectively and efficiently address the infectious disease consequences of opioid use and injection drug use. Performance Reports: Annual Federal Financial Reports (FFR) and performance/progress reports are required. Final FFRs and performance reports are required. Other reporting may be required and will be outlined in the NOFO or the Notice of Award. Not applicable. In accordance with 2 CFR ?200, as codified in 45 CFR ?75, there is a 3-year record retention requirement; records shall be retained beyond the 3-year period if final audit has not been done or findings resolved. Property records must be retained in accordance with HHS Grants Policy Statement requirements. Statutory formula is not applicable to this assistance listing.

Matching requirements are not applicable to this assistance listing.

MOE requirements are not applicable to this assistance listing. Financial assistance is provided for a 12-month budget period with a period of performance of up to five years subject to the availability of funds and satisfactory progress of the recipient. Notice of Award None/Not specified. Megan B. Copeland
1600 Clifton Road, MS E-07
Atlanta, GA 30096 US
mzf3@cdc.gov
Phone: 4046398864

Nicolas Rankin
1600 Clifton Road, MS E-07
Atlanta, GA 30329 USA
xkx6@cdc.gov
Phone: 4044980226 75-0953-0-1-550 (Cooperative Agreements) FY 22$9,828,412.00; FY 23 est $9,199,727.00; FY 24 est $9,199,727.00; - Range: $750,000 to $9,250,000, Average: $5,000,000 Not applicable. Not applicable.